ClinicalTrials.gg
CompletedNCT04536792Updated Apr 16, 2024

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

A Phase 1 interventional study of AG-946 and AG-946 Matched Placebo in Healthy Volunteers and Anemia, Sickle Cell, sponsored by Agios Pharmaceuticals, Inc.. Completed at 10 sites in 3 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
90th of 559
122 · median 31
Started
2020
with 46 others
Phase 1
98 of 733
13 open now
Registered
511th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 90th largest by enrollment of the 559 interventional ones that give a count, is one of 47 that started in 2020, is one of 98 in phase 1, and was the 511th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety and tolerability of AG-946 in healthy volunteers after oral administration of single ascending doses (SAD) and multiple ascending doses (MAD) of AG-946 over 14 or up to 28 days of dosing, and to identify a range of doses that are safe and pharmacologically active in participants with sickle cell disease. The SAD and MAD parts of the study will be randomized and double-blinded, and will assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of AG-946 as well as the effect of food (SAD only) on the pharmacokinetics (PK) of AG-946. The sickle cell disease (SCD) part of the study will be non-randomized and open-label, and is designed to identify 1 or more safe and tolerable dose(s) of AG-946 with potential activity in the treatment of participants with sickle cell disease (SCD).

03

Conditions studied

  • Healthy Volunteers
  • Anemia, Sickle Cell

Browse trials for

Keywords

  • Sickle Cell Disease
  • Healthy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

SAD and MAD

  • Participant is a healthy male or a female of nonchildbearing potential aged 18 to 55 years inclusive at the time of consent;
  • Participant is able to understand and provide before the conduct of any protocol-specific screening procedures;
  • Participant is willing and able to complete all study assessments and procedures;
  • Participant has a bodyweight ≥50 kilograms (kg) and ≥18.5 and ≤32 kilograms per square meter (kg/m\^2) at screening;
  • Participant is in good general health with no deviations from normal in screening medical history, physical examination, vital signs, or (ECGs);
  • Male participants must agree to be abstinent as part of their usual lifestyle or use up to 90 days after last dose of study treatment;
  • Participant is a non-smoker and has not used nicotine-containing products for at least 3 months prior to screening;
  • Participant is willing to refrain from caffeine- or xanthene-containing products (eg, coffee, tea, cola, chocolate) for 48 hours before the first dose of study treatment through 7 days after the last dose of study treatment;
  • Participant is willing to refrain from marijuana- or cannabinol-containing products for 7 days before admission through the final visit;
  • Participant is willing to refrain from strenuous exercise starting 72 hours before admission through the final visit;
  • Participant is willing to refrain from use of alcohol starting 7 days prior to admission through final visit;
  • Participant agrees not to donate blood products for duration of study participation;
  • Male participants must agree not to donate sperm for duration of study and for 90 days after the last dose.

Exclusion Criteria:

SAD and MAD

  • Participant has previously enrolled in this study or has received an drug with 3 months or 5 half-lives of the drug, whichever is longer, before the first dose of study treatment;
  • Participant has previously received AG-946, except for participants who are dosing in the fed portion of the food-effect group;
  • Participant has a heart rate- interval (QTc) interval using Fridericia correction method (QTcF) >450 milliseconds (ms) at screening;
  • Participant has used over-the-counter medication (excluding routine vitamins) within 7 days of the first dose of study treatment, unless agreed as not clinically relevant;
  • Participant has used acetaminophen greater than 2 grams (g) in any 24-hour period up to 48 hours before the first dose of study treatment;
  • Participants has clinically relevant screening laboratory tests results outside the normal range;
  • Participant has a history of any relevant cardiovascular, renal, hepatic, chronic respiratory, or gastrointestinal disease; or hematologic, lymphatic, neurologic, endocrine, psychiatric, musculoskeletal, genitourinary, immunologic, dermatologic, or connective tissue disease or disorders;
  • Participant has a history of serious mental illness, that includes, but is not limited to schizophrenia, bipolar disorder, or major depression;
  • Participant has a history of any primary , except for basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ or other malignancies that have been curatively treated and with no evidence of disease for at least 5 years before screening;
  • Participant has had surgery within 6 months before the first dose of study treatment;
  • Participant has a preexisting condition that interferes with normal gastrointestinal anatomy or motility, and/or hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of the study treatment or has previously undergone cholecystectomy;
  • Participant has systolic blood pressure (BP) ≥140 mm Hg or a diastolic BP of ≥90 mm Hg after 10 minutes rest at screening or before the first dosing of study treatment;
  • Participant has medical or psychological condition deemed by the Investigator to be likely to interfere with the volunteer's ability to provide informed consent, cooperate, and/or participate in the study;
  • Participant has a known allergy to any of the or components of the study treatment;
  • Participant tests positive for surface antigen (HBsAg), virus (HCV) antibody (Ab), or (HIV) infection -1 or -2 Ab;
  • Participant has donated blood, had blood loss of more than 500 milliliters (mL), or has received transfusion of blood or plasma within 3 months before screening;
  • Participant has a history of illicit drug abuse or alcoholism within the last 1 year before screening;
  • Participant has consumed more than 21 units of alcohol a week within the last 1 year before screening;
  • Participant has used prescription drugs within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study treatment;
  • Participant has a positive screen for drugs of abuse or urinary cotinine >200 nanograms per milliliter (ng/mL) at screening or admission; or a positive screen for alcohol (via urine analysis) at admission;
  • Participant cannot communicate reliably with the Investigator;
  • Participant cannot or is unlikely to cooperate with the requirements of the study;
  • Participant has any conditions that, in the judgment of the Investigator, would make the volunteer unsuitable for enrollment or could interfere with the volunteer's participation in, or completion of, the study;
  • Participant has known glucose-6-phosphate dehydrogenase (G6PD) deficiency or G6PD activity below the lower limit of the normal range at the screening visit.

Inclusion Criteria:

SCD

  • Participant is a male or female aged 18 to 70 years inclusive at the time of consent;
  • Participant has documented sickle cell anemia;
  • Provided informed consent before the conduct of any protocol-specific screening procedures;
  • If the participant is taking hydroxyurea (HU), L-glutamine, and/or crizanlizumab, the dose(s) must have been stable for at least 3 months before the first dose of AG-946;
  • Participant must start or continue to take folic acid in the equivalent of at least 0.8 milligrams per day (mg/day) orally for the duration of the study, unless the Investigator considers dietary folic acid intake to be adequate;
  • Participant has adequate organ function;
  • Female participants who are of , must have negative pregnancy test during screening;
  • Female participants who are of childbearing potential and male participants who have partners who are females of childbearing potential, must agree to be abstinent as part of their usual lifestyle or agree to use contraception from the time of providing informed consent to 28 days for women and 90 days for men after the last dose of AG-946;
  • Participant must be willing to comply with all study procedures for the duration of the study.

Exclusion Criteria:

SCD

  • Participant is a candidate for potentially curative treatment with bone marrow transplantation, and for whom participation in this study would delay or preclude such definitive treatment;
  • Participant has documented history of pyruvate kinase deficiency (PKD) or red blood cell-specific form of pyruvate kinase (PKLR) mutation;
  • Participant has had more than 6 vaso-occlusive crisis (VOCs) within the past 12 months that required a hospital, emergency room, or clinic visit;
  • Participant is receiving regularly scheduled red blood cell (RBC) transfusion therapy, and/or has received a transfusion within the past 3 months before the first dose of AG-946;
  • Participant is currently receiving treatment with voxelotor or any other agent intended to increase (Hb)-oxygen affinity;
  • Participant has a significant medical condition that confers an unacceptable risk to participating in the study, and/or that could confound the interpretation of the study data as follows:

    1. Poorly controlled hypertension (defined as systolic BP >150 millimeters of mercury (mm Hg) or diastolic BP >90 mm Hg) to medical management
    2. Any history of congestive heart failure; myocardial infarction; unstable angina pectoris; hemorrhagic, embolic, or thrombotic stroke; or recent venous thrombosis or pulmonary or arterial embolism
    3. Cardiac dysrhythmias judged as clinically significant by the Investigator
    4. QTcF >450 milliseconds (ms), unless related to right or left bundle branch block
    5. Clinically symptomatic cholelithiasis or cholecystitis
    6. History of drug-induced cholestatic hepatitis
    7. Iron overload sufficiently severe to result in a clinical diagnosis by the Investigator of cardiac, hepatic, or pancreatic dysfunction
    8. Have a diagnosis of any other congenital or acquired blood disorder, or any other hemolytic process as defined by a positive direct antiglobulin test, except for mild alloimmunization as a consequence of transfusion therapy
    9. Positive test for HBsAg, or positive test for HCV Ab with evidence of active virus infection
    10. Positive test for HIV-1 or -2 Ab
    11. Active infection requiring the use of parenteral antimicrobial agents or Grade ≥3 in severity
    12. Diabetes mellitus judged to be under poor control by the Investigator or requiring >2 antidiabetic agents, including insulin
    13. History of any primary malignancy, except for curatively treated nonmelanoma skin cancer, cervical or breast carcinoma in situ, prostate cancer, or other primary tumor treated with curative intent, no known active disease present, and no treatment administered during the last 3 years before Screening
    14. Unstable extramedullary hematopoiesis that could pose a risk of imminent neurologic compromise
    15. Current or recent history of a psychiatric disorder
  • Participant is currently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo;
  • Participant has had exposure to any investigational drug within 3 months or 5 half-lives of the drug, whichever is longer, before the first dose of AG-946;
  • Participant has had exposure to any investigational device or invasive procedure within 3 months before the first dose of AG-946;
  • Participant has a history of major surgery within 6 months of providing informed consent;
  • Participant has had a prior bone marrow or stem cell transplant;
  • Participant is currently pregnant or breastfeeding;
  • Participant has received medications that are strong inhibitors of permeability-glycoprotein (P-gp) within 5 days or a time frame equivalent to 5 half-lives (whichever is longer) before the first dose of AG-946;
  • Participant has received hematopoietic stimulating agents within 28 days before the first dose of AG-946;
  • Participant has a known allergy to any of the excipients found in AG-946.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Part 1: Single Ascending Dose (SAD) Phase

    Participants will receive a range of doses of AG-946 or placebo, orally, once on Day 1. AG-946 will be given under fasted or fed conditions.

    Drug: AG-946 · Drug: AG-946 Matched Placebo

  • Experimental
    Part 2: Multiple Ascending Dose (MAD) Phase

    Participants will receive a range of doses of AG-946 or placebo, orally, once daily (QD) for 14 days or using an alternative dosing regimen for up to 28 days under fasted conditions.

    Drug: AG-946 · Drug: AG-946 Matched Placebo

  • Experimental
    Part 3: Sickle Cell Disease (SCD) Phase

    Participants will receive a range of selected ascending doses of AG-946, orally, QD or using an alternative dosing regimen for 28 days.

    Drug: AG-946

Interventions

  • DrugAG-946

    AG-946, oral encapsulated coated-granules or tablets.

  • DrugAG-946 Matched Placebo

    AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.

06

What researchers measure

Primary outcomes

  1. SAD and MAD: Number of Participants Who Experienced at Least One Adverse Event (AE), by Severity

    Time frame: SAD: Up to Day 13; MAD: Up to Day 49

  2. SAD and MAD: Number of Participants Who Experienced at Least One AE Related to the Study Drug

    Time frame: SAD: Up to Day 13; MAD: Up to Day 49

  3. SAD and MAD: Number of Participants Who Experienced at Least One Serious Adverse Event (SAE)

    Time frame: SAD: Up to Day 13; MAD: Up to Day 49

  4. SAD and MAD: Number of Participants With Clinically Significant Laboratory Abnormalities, by Severity

    Time frame: SAD: Up to Day 13; MAD: Up to Day 49

  5. SAD and MAD: Number of Participants With Clinically Significant Changes in Vital Signs and in Electrocardiogram (ECG) Parameters

    Time frame: SAD: Up to Day 13; MAD: Up to Day 49

  6. SCD: Number of Participants Who Experienced at Least One AE, by Severity

    Time frame: Up to Day 56

  7. SCD: Number of Participants Who Experienced at Least One AE Related to the Study Drug

    Time frame: Up to Day 56

  8. SCD: Number of Participants Who Experienced at Least One SAE

    Time frame: Up to Day 56

  9. SCD: Number of Participants With Clinically Significant Laboratory Abnormalities, by Severity

    Time frame: Up to Day 56

  10. SCD: Number of Participants With Clinically Significant Changes in Vital Signs and in ECG Parameters

    Time frame: Up to Day 56

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of AG-946

    Cmax will be determined under fasted and fed conditions in SAD and under fasted conditions only in MAD and SCD.

    Time frame: SAD: Up to Day 8; MAD: Up to Day 49; SCD: Up to Day 56

  2. Time to Reach Maximum Observed Concentration (Tmax) of AG-946

    Tmax will be determined under fasted and fed conditions in SAD and under fasted conditions only in MAD and SCD.

    Time frame: SAD: Up to Day 8; MAD: Up to Day 49; SCD: Up to Day 56

  3. Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-t), Time Curve from Time Zero to Infinity (AUC0-∞), and Time Curve from Time Zero to Time tau Over the Dosing Interval (AUC0-τ) for AG-946

    AUC0-t, AUC0-∞, and AUC0-τ will be determined under fasted and fed conditions in SAD and under fasted conditions only in MAD and SCD.

    Time frame: SAD: Up to Day 8; MAD: Up to Day 49; SCD: Up to Day 56

  4. SAD: Apparent Clearance (CL/F) for AG-946

    CL/F will be determined under fasted and fed conditions.

    Time frame: SAD: Up to Day 8

  5. SAD: Apparent Volume of Distribution (Vd/F) for AG-946

    V/F will be determined under fasted and fed conditions.

    Time frame: SAD: Up to Day 8

  6. SAD: Total Amount of Drug Excreted in Urine from Time 0 to Time T (Aet) and from Time t1 to Time t2 (Aet1-t2) for AG-946 Under Fasted and Fed Conditions

    Time frame: Up to Day 3

  7. SAD: Percentage Dose of Drug Excreted in Urine from Time 0 to Time t (fet) and from Time t1 to Time t2 (fet1-t2) for AG-946 Under Fasted and Fed Conditions

    Time frame: Up to Day 3

  8. SAD: Renal Clearance (CLr) for AG-946 Under Fasted and Fed Conditions

    Time frame: Up to Day 3

  9. Changes in the Concentration of 2,3-diphosphoglycerate (2,3-DPG) and Adenosine Triphosphate (ATP) in Whole Blood

    Time frame: SAD: Up to Day 13; MAD: Up to Day 49; SCD: Up to Day 56

  10. Area Under the Effect Curve (AUEC) from Time zero to t for 2,3-DPG and ATP

    Time frame: SAD: Up to Day 13; MAD: Up to Day 49; SCD: Up to Day 56

  11. SAD: Relative Bioavailability Comparing Fasted to Fed Conditions Determined from the PK Parameters of AG-946

    Time frame: SAD: Up to Day 8

  12. SCD: Change From Baseline in Hemoglobin (Hb)

    Time frame: Up to Day 56

  13. SCD: Change From Baseline in Direct Bilirubin

    Time frame: Up to Day 56

  14. SCD: Change From Baseline in Lactate Dehydrogenase (LDH)

    Time frame: Up to Day 56

  15. SCD: Change From Baseline in Haptoglobin

    Time frame: Up to Day 56

  16. SCD: Change From Baseline in Reticulocytes

    Time frame: Up to Day 56

  17. SCD: Change From Baseline in Erythropoietin

    Time frame: Up to Day 56

07

Study locations

10 sites
  • University of California San Diego
    La Jolla, California 92037, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • New York Presbyterian Hospital - Weill Cornell Medicine
    New York, New York 10065, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • PPD Development, LP
    Austin, Texas 78744, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center - USOR
    Dallas, Texas 75246, United States
  • University of Texas Health Science Center of Houston
    Houston, Texas 77030, United States
  • Rigshospitalet, Department of Hematology
    Copenhagen, 2100, Denmark
  • Hospital Universitario Vall d'Hebron - PPDS
    Barcelona, 08035, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Dec 2023, 41 months.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 41 months is above that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2020
First posted
Sep 3, 2020
StartActual
Jul 10, 2020
Primary completionActual
Dec 19, 2023
CompletionActual
Dec 19, 2023
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04536792
Responsible party
Sponsor
First posted
Sep 3, 2020
Start date
Jul 10, 2020
Primary completion
Dec 19, 2023
Completion
Dec 19, 2023
Last update
Apr 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebapivat

Start the discussion